Syros pushes for a turnaround with new PhII AML results, but investors are unimpressed
Two years after weak Phase II results cut their stock price in half, Syros Pharmaceuticals (SYRS) is back with results from an ongoing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
